Nasopharyngeal Airway Combined With Nasal High-flow Oxygen Therapy During Painless Gastroscopy in Obesity Patients

Launched by NANJING FIRST HOSPITAL, NANJING MEDICAL UNIVERSITY · May 12, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how a combination of two tools, a nasopharyngeal airway (NPA) and high-flow nasal oxygen therapy (HFNC), can help improve breathing for obese patients undergoing a painless gastroscopy. Gastroscopy is a procedure used to look inside the digestive tract, but it can sometimes make patients feel uncomfortable or lead to low oxygen levels, especially in those who are obese. The trial aims to see if using the NPA along with HFNC can help keep oxygen levels stable and make the procedure safer and more comfortable for these patients.

To participate in this trial, patients need to be over 18 years old, have a body mass index (BMI) greater than 28 (which indicates obesity), and be scheduled for a painless gastroscopy. However, some patients may not be eligible, such as those with certain allergies, severe respiratory or heart issues, or ongoing infections. If eligible, participants can expect to undergo the gastroscopy with the added support of the NPA and HFNC to help manage their breathing during the procedure. This trial is not yet recruiting participants, but it aims to provide valuable information on improving care for obese patients during these examinations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients undergoing painless gastroscopy;
• • 2. Patients with an age greater than 18 years old;
• • 3. American Society of Anesthesiologists (ASA) physical status classification from Grade I to Grade III;
• • 4. Body Mass Index (BMI) greater than 28 kg/m²
• Exclusion Criteria:
• • 1. Patients with contraindications to endoscopic procedures or those who refuse sedation/anesthesia;
• • 2. Patients allergic to propofol, eggs, soybeans, milk, etc.;
• • 3. Patients with gastrointestinal tract obstruction and gastric emptying disorders;
• • 4. Patients with acute pharyngitis, tonsillitis, and upper respiratory tract infections;
• • 5. Patients in the acute exacerbation stage of respiratory diseases such as asthma, bronchitis, and chronic obstructive pulmonary disease (COPD);
• • 6. Patients with acute arrhythmia and those with severe heart diseases (congenital diseases, valvular diseases);
• • 7. Patients with severe hepatic and renal insufficiency who require alternative treatment;
• • 8. Patients with severe mental disorders who need medications to control their symptoms;
• • 9. Patients with moderate or above anemia, abnormal coagulation function, and hematological diseases;
• • 10. Patients with nasal cavity lesions leading to severe nasal congestion;
• • 11. Pregnant and lactating patients.